Business
NEW PUBLICATIONS UTILISING PARSORTIX
NEW PUBLICATIONS UTILISING PARSORTIX.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 7497W Angle PLC 29 April 2016 \n\n\n\n\n\nFor immediate release\n\n\n 29 April 2016\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nNEW PUBLICATIONS UTILISING PARSORTIX\n \nNew data from key opinion leaders on research undertaken with the Parsortix system released at AACR and ISMRC conferences\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is pleased to announce that, following highly successful meetings at AACR 2016 (the American Association for Cancer Research Annual Meeting 2016 in New Orleans) and ISMRC (the 10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment in Hamburg), several scientific poster presentations published by key opinion leaders have now been released to ANGLE's website.\n \nThe published poster presentations can be found at http://www.angleplc.com/the-parsortix-system/download-files/ and are as follows:\n \n1) Cancer Research UK Manchester Institute: Detection and molecular characterization of EpCAM positive and EpCAM negative circulating tumour cells isolated from SCLC (small cell lung cancer) patients using an epitope independent platform\n \n2) Cancer Research UK Manchester Institute: Integration of RNA and DNA blood borne cancer biomarkers\n \n3) Cancer Research UK Manchester Institute: Combined circulating tumour cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer\n \n4) Heinrich-Heine University, Düsseldorf, Germany: The combination of Parsortix™ system and CellCelector™ micromanipulator enables the characterization of EpCAM negative circulating tumor cells in breast cancer\n \nThe published poster presentations add to the growing published evidence in support of the use of ANGLE's Parsortix system to easily and effectively harvest cancer cells from the blood of patients for analysis.\n \nKey points in the published posters includes:\n \n· Development of a robust protocol for the isolation and storage of CTCs. This is of great value for the incorporation of the system in clinical trials;\n \n· Demonstration of the ability to store CTCs once harvested from Parsortix for long periods, facilitating the us...